New Mexico Alzheimer's Disease Research Center

摘要(总体核心) 这项提议是在新墨西哥州建立一个探索性的阿尔茨海默病研究中心(NM EADRC)。该中心的目标是：1)建立基础设施并雇用教员来加强阿尔茨海默氏症 (Ad)研究；2)满足健康差距较大的农村社区的需要；3)使用 多模式生物标记物，包括脑脊液和核磁共振，将血管疾病纳入新的NIA-AA 阿尔茨海默病(AD)生物学定义，改善患者策略。这个P20 NM eADRC将 向P30 ADRC进军。我们计划招聘具有阿尔茨海默病(AD)专业知识的新教员 相关痴呆(RD)。通过建设新的养老基础设施满足老年人的养老需求 耗资700万美元的大楼将容纳三个中心：运动障碍中心、老年医学中心和 记忆和衰老，在照顾老年人方面创造协同效应。NM eADRC将解决未满足的问题 痴呆症护理需求与差异有关，特别是在庞大的美洲印第安人(AI)人口中。 改善对人工智能的痴呆症护理面临着挑战，包括文化不敏感、低收入和 受教育程度高，需要长途旅行接受专科护理。我们将通过以下方式克服这些障碍 使用社区卫生代表进行认知筛查和现场移动项目 筛查和测试(MOSST)，包括神经心理测试和移动1.5T MRI 成像。这将填补国家AD数据库中有关少数民族的数据的空白。血管疾病是一种 主要与AD并存，加速认知能力下降。据估计，高达70%的 非遗传性阿尔茨海默病是混合性痴呆(MX)，这使其成为尸检前需要确认的重要群体。我们 已经开发出可以成功地对患者进行分层的生物标记物。这涉及到脑脊液和核磁共振的使用。 研究并允许将血管特征(V)添加到淀粉样蛋白(A)、tau(T)和 NIA-AA公式中用于诊断AD的神经退行性变(N)成分。脑脊液中的生物标志物 已被MarkVCID财团确认为炎症，当两者都发生时 AD和血管疾病是存在的。NM eADRC将测量这些独特的生物标志物 新招募的参与者，并向其他有兴趣的ADRC提供这些服务。血- 脑屏障(BBB)参与了阿尔茨海默病的病理生理过程。我们计划测量血脑屏障 AD和RD患者的灰质和白质通透性与VCID和MX的改善 了解它在痴呆症中的作用。NM eADRC将是对一个大型社区进行AD研究的基础 研究人员遍布全州，并将成为医学院管理结构内的主要中心。 有能力引进新的教员，建造新的建筑，并将科学家社区聚集在一起 对NM的痴呆症感兴趣，它将产生巨大的影响，将为 P30中心申请成功。

ABSTRACT (Overall Core) This proposal is to establish in New Mexico an exploratory Alzheimer's Disease Research Center (NM eADRC). The Center goals are: 1) to build infrastructure and hire faculty to enhance Alzheimer's disease (AD) research; 2) to meet the needs of rural communities with health disparities, and 3) to use multimodal biomarkers, including CSF and MRI, to incorporate vascular disease into the new NIA-AA Alzheimer's disease (AD) biological definition, improving patient stratefication. This P20 NM eADRC will build toward the P30 ADRC. We plan to hire new faculty with expertise in Alzheimer's disease (AD) and related dementias (RD). Infrastructure needs for care of the elderly will be met by the construction of new 7 million dollar building that will house three centers: Movement disorders, Geriatrics, and Center for Memory and Aging, creating synergy in care of the elderly. The NM eADRC will address the unmet needs in dementia care related to disparities, particularly in the large American Indian (AI) population. There are challenges to improving dementia care to AI that include cultural insensitivity, low income and educational levels, and long distances to travel for specialist care. We will overcome these barriers by using community health representatives to perform cognitive screening and a program for mobile on-site screening and testing (MOSST) that includes neuropsychological testing and mobile 1.5T MRI for imaging. This will fill a gap in the national AD databases for data on minorities. Vascular disease is a major co-morbidity with AD that accelerates the cognitive decline. It is estimated that up to 70% of nongenetic AD is mixed dementia (MX), making this an important group to identify prior to autopsy. We have developed biomarkers that can successfully stratify patients. This involves the use of CSF and MRI studies, and allows for the addition of the vascular feature (V) to the amyloid (A), tau (T), and neurodegeneration (N) components of the NIA-AA formula for diagnosis of AD. Biomarkers in the CSF have been identified by the MarkVCID consortium that indicate inflammation, which occurs when both AD and vascular disease are present. The NM eADRC will measure these unique biomarkers in the newly recruited participants, and provide these services to other ADRCs that are interested. The blood- brain barrier (BBB) has been implicated in the pathophysiology of AD. We plan to measure BBB permeability in gray and white matter in patients with AD and RD along with VCID and MX to better understand its role in dementia. The NM eADRC will be nidus for AD research to a large community of researchers around the state and will be major center within the Medical School Administrative structure. With the ability to bring in new faculty, build new buildings, and bring together the community of scientists interested in dementia in NM, it will make a huge impact that will provide the infrastructure for a successful P30 Center application.